Evaluation of Mass Balance and Absolute Bioavailability of GLPG3667

PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

April 19, 2022

Primary Completion Date

June 3, 2022

Study Completion Date

June 3, 2022

Conditions
Healthy
Interventions
DRUG

GLPG3667 capsule

On Day 1, participants will receive a single oral dose of GLPG3667

DRUG

[14C]-GLPG3667 solution for infusion

On Day 1, participants will receive a single microtracer microdose of \[14C\]-GLPG3667 as an intravenous infusion

DRUG

[14C]-GLPG3667 capsule

On Day 1, participants will receive a single oral dose of \[14C\]-GLPG3667

Trial Locations (1)

NG11 6JS

Quotient Sciences Limited, Nottingham

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Galapagos NV

INDUSTRY

NCT05335447 - Evaluation of Mass Balance and Absolute Bioavailability of GLPG3667 | Biotech Hunter | Biotech Hunter